ADVM Adverum Biotechnologies Inc
Price (delayed)
$3.94
Market cap
$81.96M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.99
Enterprise value
$49.74M
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate,
Highlights
ADVM's EPS has soared by 52% YoY and by 25% QoQ
Adverum Biotechnologies's net income has increased by 25% YoY and by 6% QoQ
The quick ratio has grown by 41% YoY but it has contracted by 28% from the previous quarter
Adverum Biotechnologies's equity has increased by 40% YoY but it has decreased by 14% QoQ
ADVM's gross profit has shrunk by 72% YoY
ADVM's revenue has dropped by 72% year-on-year
Key stats
What are the main financial stats of ADVM
Market
Valuations
Earnings
Shares outstanding
20.8M
Market cap
$81.96M
Enterprise value
$49.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
82.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.74
Revenue
$1M
Gross profit
$1M
Operating income
-$103.1M
Net income
-$94.11M
EBIT
-$95.24M
EBITDA
-$89.26M
Free cash flow
-$86.06M
Per share
Balance sheet
Liquidity
EPS
-$5.99
EPS diluted
-$5.99
Free cash flow per share
-$4.12
Book value per share
$6.93
Revenue per share
$0.05
TBVPS
$11.23
Total assets
$234.38M
Total liabilities
$90.26M
Debt
$62.6M
Equity
$144.12M
Working capital
$133.42M
Debt to equity
0.43
Current ratio
5.82
Quick ratio
5.87
Net debt/EBITDA
0.36
Margins
Efficiency
Dividend
EBITDA margin
-8,926%
Gross margin
100%
Net margin
-9,411.1%
Operating margin
-10,310%
Return on assets
-40.5%
Return on equity
-65.1%
Return on invested capital
-60.1%
Return on capital employed
-46.1%
Return on sales
-9,524.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADVM stock price
How has the Adverum Biotechnologies stock price performed over time
Intraday
-1.01%
1 week
-11.66%
1 month
-10.45%
1 year
-80%
YTD
-15.63%
QTD
-15.63%
Financial performance
How have Adverum Biotechnologies's revenue and profit performed over time
Revenue
$1M
Gross profit
$1M
Operating income
-$103.1M
Net income
-$94.11M
Gross margin
100%
Net margin
-9,411.1%
Adverum Biotechnologies's operating margin has shrunk by 182% YoY
Adverum Biotechnologies's net margin has shrunk by 168% YoY
ADVM's gross profit has shrunk by 72% YoY
ADVM's revenue has dropped by 72% year-on-year
Growth
What is Adverum Biotechnologies's growth rate over time
Valuation
What is Adverum Biotechnologies stock price valuation
P/E
N/A
P/B
0.57
P/S
82.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.74
ADVM's EPS has soared by 52% YoY and by 25% QoQ
The price to book (P/B) is 59% lower than the 5-year quarterly average of 1.4 and 48% lower than the last 4 quarters average of 1.1
Adverum Biotechnologies's equity has increased by 40% YoY but it has decreased by 14% QoQ
ADVM's revenue has dropped by 72% year-on-year
Efficiency
How efficient is Adverum Biotechnologies business performance
ADVM's ROS has shrunk by 172% YoY
Adverum Biotechnologies's return on equity has increased by 26% YoY and by 13% QoQ
The company's return on assets rose by 18% YoY and by 10% QoQ
Adverum Biotechnologies's return on invested capital has increased by 13% QoQ and by 4.3% YoY
Dividends
What is ADVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADVM.
Financial health
How did Adverum Biotechnologies financials performed over time
The total assets is 160% greater than the total liabilities
The quick ratio has grown by 41% YoY but it has contracted by 28% from the previous quarter
ADVM's current ratio is up by 35% year-on-year but it is down by 27% since the previous quarter
Adverum Biotechnologies's debt is 57% lower than its equity
Adverum Biotechnologies's equity has increased by 40% YoY but it has decreased by 14% QoQ
Adverum Biotechnologies's debt to equity has decreased by 32% YoY but it has increased by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.